🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Egypt / NCT07427446
Recruiting Phase 4

Dexmedetomidine-Midazolam vs. Ketamine-Midazolam on Emergence Delirium

NCT07427446 · tracked via the Priya Life Science Egypt tracker
Phase
Phase 4
Started
2026-02-01
Last updated
2026-02-27

Condition(s) studied

Emergence Delirium

Investigational drug(s) / intervention(s)

Dexmedetomidine and MidazolamKetamine and Midazolam

Dexmedetomidine and Midazolam: Children will receive Dexamedetomedine and Midazolam

Ketamine and Midazolam: Children will receive Ketamine and Midazolam

Study summary

Fifty children undergoing heart catheterization without local anesthesia in the skin will be randomly divided into two groups.

Group DM (Dexmedetomidine + Midazolam) and Group KM (Ketamine + Midazolam)

Eligibility

Sex
ALL
Min age
2 Years
Max age
6 Years
Healthy volunteers
No
Inclusion Criteria: * Scheduled for elective cardiac catheterization under general anesthesia. Exclusion Criteria: * neurological disorder, psychiatric disease, or current psychoactive medication. * allergy. * significant systemic comorbidities.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Kasralainy Hospital Cairo Egypt Recruiting

More Kasr El Aini Hospital trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07427446 on ClinicalTrials.gov ↗ ← All trials in Egypt